Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
MP-Myeloma Regimen
Known as:
Melphalan-Prednisone Regimen
A regimen consisting of melphalan and prednisone used as induction treatment for multiple myeloma.
National Institutes of Health
Create Alert
Related topics
Related topics
4 relations
Melphalan
Multiple Myeloma
Prednisone
melphalan/prednisone protocol
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple…
J. San-Miguel
,
Maria-Asunción Echeveste Gutierrez
,
+13 authors
S. Lonial
Haematologica
2018
Corpus ID: 49590938
This phase I/II dose-escalation study investigated the all-oral ixazomib-melphalan-prednisone regimen, followed by single-agent…
Expand
Review
2016
Review
2016
Treatment of Newly Diagnosed Elderly Multiple Myeloma.
G. Fouquet
,
F. Gay
,
+5 authors
A. Palumbo
Cancer treatment and research
2016
Corpus ID: 46252980
Multiple myeloma (MM) is a disease of the elderly, with a median age at diagnosis of approximately 70 years old, and more than 30…
Expand
2014
2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy
M. Mateos
,
S. Bringhen
,
+12 authors
A. Palumbo
Haematologica
2014
Corpus ID: 44993861
Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible…
Expand
2014
2014
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies
S. Caltagirone
,
M. Ruggeri
,
+14 authors
P. Omede'
Haematologica
2014
Corpus ID: 16736815
Multiple myeloma is a plasma cell disorder characterized by malignant plasma cell infiltration in the bone marrow, serum and/or…
Expand
2014
2014
Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies RUNNING HEAD : Chr 1 abnormalities in MM treated with new drugs
S. Caltagirone
,
M. Ruggeri
,
+14 authors
Paola Omedè Haematologica
2014
Corpus ID: 33973668
Multiple Myeloma is a plasma cell disorder, characterized by malignant plasma cell infiltration in the bone marrow, serum and/or…
Expand
Review
2013
Review
2013
Incorporating Novel Agents in the Management of Elderly Myeloma Patients
T. Guglielmelli
,
A. Palumbo
Current Hematologic Malignancy Reports
2013
Corpus ID: 22805365
In recent years, the treatment of multiple myeloma has undergone significant changes. The availability of novel agents bortezomib…
Expand
Review
2007
Review
2007
New therapies in multiple myeloma
F. Merchionne
,
F. Perosa
,
F. Dammacco
Clinical and Experimental Medicine
2007
Corpus ID: 10747053
The melphalan-prednisone regimen has been considered as standard therapy for patients with multiple myeloma (MM) for many years…
Expand
Review
2006
Review
2006
Thalidomide in multiple myeloma: past, present and future.
J. Harousseau
Future oncology
2006
Corpus ID: 43591800
Thalidomide was introduced in the treatment of multiple myeloma in the late 1990s. Following the initial results, which…
Expand
2002
2002
Current treatment strategies for multiple myeloma.
B. Grosbois
,
O. Decaux
,
I. Azais
,
T. Façon
,
H. Avet-Loiseau
European journal of internal medicine
2002
Corpus ID: 44646092
Until 1990, the melphalan-prednisone regimen was the standard treatment for multiple myeloma (MM). The role of alpha-interferon…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE